Taipei City, Taiwan
Summary
This company is focused on the development of innovative oncology drugs, specifically targeting anti-cancer therapies. They are engaged in both pre-clinical and clinical stages of drug development, with a commitment to ethical practices and sustainable development. Their product pipeline includes several novel drug candidates aimed at addressing unmet medical needs in cancer treatment.
Based on content on taivex.com
No similar companies found
We offer API access to our data.
8 of 8 checks passed
Label
Value
Active Dates
14.0 years — Since Jan 2011
Web Hosting
Platform
E-Mail Provider
NAICS Code
325412
SIC 4 Digit Code
2834
SIC 2 Digit Code
28
Industry
1. Pharmaceuticals and Biotechnology
2. Pharmaceutical Preparation Manufacturing
Vendor
Source
Microsoft
TXT Record
Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2011 |
|
|
|
|
|
|
|
|
|
|
|
|
2012 |
|
|
|
|
|
|
|
|
|
|
|
|
2013 |
|
|
|
|
|
|
|
|
|
|
|
|
2014 |
|
|
|
|
|
|
|
|
|
|
|
|
2015 |
|
|
|
|
|
|
|
|
|
|
|
|
2016 |
|
|
|
|
|
|
|
|
|
|
|
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
2018 |
|
|
|
|
|
|
|
|
|
|
|
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
|
2020 |
|
|
|
|
|
|
|
|
|
|
|
|
2021 |
|
|
|
|
|
|
|
|
|
|
|
|
2022 |
|
|
|
|
|
|
|
|
|
|
|
|
2023 |
|
|
|
|
|
|
|
|
|
|
|
|
2024 |
|
|
|
|
|
|
|
|
|
|
|
|